Difluprednat
 | |
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Oftalmički |
| Identifikatori | |
| CAS broj | 23674-86-4  Y |
| ATC kod | D07AC19 (WHO) |
| PubChem | CID 443936 |
| DrugBank | DB06781 Y |
| ChemSpider | 391990 Y |
| ChEMBL | CHEMBL1201749 Y |
| Hemijski podaci | |
| Formula | C27H34F2O7 |
| Molarna masa | 508,551 |
SMILES
| |
InChI
| |
Difluprednat je organsko jedinjenje, koje sadrži 27 atoma ugljenika i ima molekulsku masu od 508,551 Da.[1][2][3][4][5]
Osobine
| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 7 |
| Broj donora vodonika | 1 |
| Broj rotacionih veza | 8 |
| Particioni koeficijent[6] (ALogP) | 3,1 |
| Rastvorljivost[7] (logS, log(mol/L)) | -5,5 |
| Polarna površina[8] (PSA, Å2) | 107,0 |
Reference
- ^ Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS: Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009 Jan;35(1):26-34. PMID 19101421
- ^ Jamal KN, Callanan DG: The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29. PMID 19668594
- ^ Morton KD, Van de Kar LD, Brownfield MS, Bethea CL: Neuronal cell bodies in the hypothalamic paraventricular nucleus mediate stress-induced renin and corticosterone secretion. Neuroendocrinology. 1989 Jul;50(1):73-80. PMID 2666872
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126. уреди - ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. уреди
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди
Literatura
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
- Difluprednate
- p
- r
- u
(3-on, 4-en,
bez fg u 16)
- Pregnendion: Aldosteron
- 11-Deoksikortikosteron
- halogenisan u 9: Fludrokortizon
(3-on, 4-en,
11-FG,
17-hidroksi)
| Pregnen | |
|---|---|
| Pregnendion (+20-one) |
|
| Pregnadien (+1-en) |
|
| Pregnadiendiol (+21-hidroksi) |
|
| Pregnadientriol (+11-hidroksi) |
|
| Pregnatrien (+2-en) | |
| Androsten |
|
| Drugi/negrupisani |
|
- #WHO-EM. ‡Povučeni sa tržišta. Kliničko ispitivanje: †Faza III. §Nikad do faze III
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
Difluprednat na srodnim projektima Vikipedije:
Mediji na Ostavi
Podaci na Vikipodacima
